Pulmonary Fibrosis clinical trials
The registry lists 342 studies for Pulmonary Fibrosis across more than 10 countries. 98 are recruiting or about to start. 144 of them are mainly about Pulmonary Fibrosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Idiopathic Pulmonary Fibrosis: 837 studies, 198 open.
Get an email when these change. Save the Pulmonary Fibrosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Heart, Lung, and Blood Institute (NHLBI) (12) · Boehringer Ingelheim (9) · National Jewish Health (6) · Bristol-Myers Squibb (6) · National Human Genome Research Institute (NHGRI) (5) · Assistance Publique - Hôpitaux de Paris (5) · Peking Union Medical College Hospital (5) · Erasmus Medical Center (4)
What is being tested here
Drugs under test in Pulmonary Fibrosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| CBP-8 gallium GA-68 | 3 | 0 | 3 |
| Pirfenidone | 2 | 3 | 11 |
| Admilparant | 1 | 3 | 4 |
| Rituximab | 1 | 3 | 4 |
| SC1011 | 1 | 1 | 3 |
| Rentosertib | 1 | 0 | 2 |
| Belumosudil | 1 | 0 | 2 |
| Fingolimod | 1 | 0 | 1 |
| Gabapentin | 1 | 0 | 1 |
| Benzonatate | 1 | 0 | 1 |
Drug classes tested here Antimetabolites 2 open · Alkylating agents 1 open · Tyrosine kinase inhibitors (TKIs) 9 · mTOR inhibitors 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis · Phase 3 · University of Chicago
- Dec 2026SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) · Phase 3 · Guangzhou JOYO Pharma Co., Ltd
- Nov 2026IPF Longitudinal Natural History Study · Assiut University
- Dec 2026Explanted Lung Tissues With Pulmonary Fibrosis · University of Chicago
- Dec 2026Treatable Traits in Interstitial Lung Disease · The University of Western Australia
- Dec 2026A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients · Sunshine Lake Pharma Co., Ltd.
- Dec 2026Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath · ChromX Health
- Dec 2026DEVELOPMENT OF INNOVATIVE TARGETED LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF INFLAMMATORY DRIVEN PULMONARY FIBROSIS · Fondazione IRCCS Policlinico San Matteo di Pavia
- Dec 2026Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis · The First Affiliated Hospital with Nanjing Medical University
- Dec 2026Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT · Taichung Veterans General Hospital
Who these studies take
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger. 8 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 12 (17%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 8 (11%) | 8 (11%) |
| 18 | 62 (87%) | 62 (87%) |
| 30 | 64 (90%) | 64 (90%) |
| 40 | 70 (99%) | 70 (99%) |
| 50 | 71 (100%) | 71 (100%) |
| 65 | 70 (99%) | 70 (99%) |
| 75 | 69 (97%) | 69 (97%) |
| 85 | 55 (77%) | 55 (77%) |
Across all 342 studies, recruiting or not: 12% stop at 75 or younger and 7% at 65; 10% take children; 1% are for women only and 1% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Pulmonary Fibrosis studies take
Of 33 phase 2 interventional studies under Pulmonary Fibrosis, half reached primary completion within 44 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 15 mo3–55 · 20 studies | — | — |
| Phase 2 | 44 mo27–75 · 33 studies | — | — |
| Interventional, no phase | 30 mo14–81 · 41 studies | — | — |
| Observational | 41 mo24–111 · 60 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Results posted1
- Low-Dose Danazol for the Treatment of Telomere Related DiseasesOct 27, 2026NCT03312400
Stopped1
- Low-Dose Danazol for the Treatment of Telomere Related DiseasesTerminatedOct 27, 2026NCT03312400
Studies
Recruiting first, then most recently updated. Showing 50 of 342. Browse all 342 → or search them.
- Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes RegistryRecruitingNCT019155111 country
- Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisRecruitingNCT07284459Phase 219 countries
- Role of Genetic Factors in the Development of Lung DiseaseRecruitingNCT000015321 country
- Clinical and Basic Investigations Into Hermansky-Pudlak SyndromeRecruitingNCT000014561 country
- Senicapoc in Patients With Worsening Fibrotic Interstitial Lung DiseaseRecruitingNCT06714123Phase 23 countries
- Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary FibrosisNot yet recruitingNCT07441408Phase 327 countries
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07284602Phase 32 countries
- Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialRecruitingNCT07482917Not applicable1 country
- Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung DiseasesRecruitingNCT06189820Phase 21 country
- Telomeres Length in Israeli Fibrotic ILD PatientsEnrolling by invitationNCT068855151 country
- Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote MonitoringRecruitingNCT07673237Not applicable1 country
- Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILDNot yet recruitingNCT07859839Phase 41 country
- Development of FAPI PET as a Non-invasive Biomarker of Pulmonary FibrogenesisRecruitingNCT06940427Phase 21 country
- Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic SclerosisNot yet recruitingNCT07839221
- Global Utilization And Registry Database for Improved preservAtion of doNor LUNGsEnrolling by invitationNCT049302892 countries
- Pulmonary Fibrosis Foundation Community RegistryRecruitingNCT053825721 country
- Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07679893Phase 21 country
- Diaphragmatic Release vs Inspiratory Muscle Training in Pulmonary FibrosisNot yet recruitingNCT07810153Not applicable
- Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT002585701 country
- Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CTRecruitingNCT077613771 country
- Nucleoside Therapy in Patients With Telomere Biology DisordersRecruitingNCT06817590Phase 11 country
- H01 in Adults With Interstitial Lung Disease (The SOLIS Study)RecruitingNCT06325696Phase 21 country
- Antifibrotic Therapy Decision-Making in Pulmonary FibrosisNot yet recruitingNCT077225071 country
- FAPI PET Imaging - An Exploratory StudyNot yet recruitingNCT07705074Phase 1/21 country
- Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisRecruitingNCT07572383Phase 21 country
- Interstitial Lung Disease Research Unit BiobankRecruitingNCT053928811 country
- A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA)RecruitingNCT076837281 country
- Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary FibrosisRecruitingNCT061628841 country
- Safety of Bronchoscopy in Patients With Interstitial Lung DiseaseNot yet recruitingNCT076275942 countries
- Better Tests- Improving Diagnostic Accuracy and Prognostication in Interstitial Lung DiseasesRecruitingNCT076155041 country
- Implementation of Home Monitoring in Patients With Pulmonary FibrosisRecruitingNCT06883448Not applicable1 country
- Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation TherapyRecruitingNCT061596601 country
- P4O2 ILD ExtensionRecruitingNCT066441441 country
- This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.Not yet recruitingNCT07570888Phase 4
- Pirfenidone to Prevent Fibrosis in Ards.RecruitingNCT05075161Phase 32 countries
- Proteogenomic Monitoring and Assessment of Kidney Transplant RecipientsRecruitingNCT015312571 country
- A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) PatientsRecruitingNCT05139719Phase 21 country
- Advanced Imaging for Pulmonary FibrosisRecruitingNCT06532071Phase 21 country
- Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary FibrosisNot yet recruitingNCT07503587Phase 3
- Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung DiseaseRecruitingNCT06751069Not applicable1 country
- Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related DiseasesRecruitingNCT07464132Phase 1/21 country
- Clinical Application of 68Ga-1A12 PET in Fibrosis-related DiseasesNot yet recruitingNCT074592051 country
- Evaluation of the Pulmonary Fibrosis Learning and Self-management Programme (FILIP)RecruitingNCT07457463Not applicable1 country
- Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis PatientsRecruitingNCT03535545Phase 11 country
- Correlation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis)Not yet recruitingNCT073932171 country
- Inspiratory Effort Assessed Through Nasal Pressure Measurement in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT053106691 country
- HOXB7 and Linked Tissue and Blood Biomarkers in the Lungs of Patients With Pulmonary FibrosisRecruitingNCT073732881 country
- Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related CoughRecruitingNCT05120934Phase 21 country
- Western Sweden Systemic Sclerosis ProjectRecruitingNCT073450521 country
- Explanted Lung Tissues With Pulmonary FibrosisRecruitingNCT005155671 country